Degenerative diseases have been a major source of concern for health practitioners. Given the advancement in technology, companies in this line of business are constantly battling to provide a cure for these diseases. Biogen’s Aduhelm approval puts it at the forefront of the fight against Alzheimer's disease and dementia. If the drug can reduce the growth of amyloid in small or mild Alzheimer cases, Biogen may see its stock value rival the likes of Amgen in the next few years.